AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- A simple urine test for selected matrix metalloproteinases may provide a novel noninvasive means of assessing a woman's risk of developing breast cancer, Dr. Susan E. Pories reported at a breast cancer symposium sponsored by the Cancer Therapy and Research Center.
Urinary levels of two biomarkers--matrix metalloproteinase-9 (MMP-9) and a disintegrin and metalloprotease 12 (ADAM12)--appear to be independent predictors of the presence of breast atypical hyperplasia or lobular carcinoma in situ (LCIS), both of which are well established predictors of increased risk of breast cancer, explained Dr. Pories of Beth Israel Deaconess Medical Center, Boston.
Dr. Pories and her coworkers had previously found that levels of MMP-9 and ADAM12 increase with more advanced disease status in patients who have breast cancer.
In the current study, she reported on urine samples obtained from 44 women with atypical ductal or atypical lobular hyperplasia, 24 with lobular carcinoma in situ, and 80 healthy controls.
For a 30-mL urine sample testing positive for both MMP-9 and ADAM12, the probability that the sample belonged to a woman with LCIS or atypical hyperplasia was 100%.
A urine sample that was MMP-9 negative but ADAM12 positive, had a 67% ...